Related Experiment Video
Updated: Aug 14, 2025

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
Published on: May 22, 2014
Chronic kidney disease and NLRP3 inflammasome: Pathogenesis, development and targeted therapeutic strategies
Gengzhen Huang1,2, Yaodan Zhang3, Yingying Zhang1
1Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
Abstract:
Chronic kidney disease (CKD) is a global health concern and public health priority. The condition often involves inflammation due to the accumulation of toxins and the reduced clearance of inflammatory cytokines, leading to gradual loss of kidney function. Because of the tremendous burden of CKD, finding effective treatment strategies against inflammation is crucial. Substantial evidence suggests an association between kidney disease and the inflammasome. As a well-known multiprotein signaling complex, the NLR family pyrin domain containing 3 (NLRP3) inflammasome plays an important role in inducing renal inflammation and fibrosis. Small molecule inhibitors targeting the NLRP3 inflammasome are potential agents for the treatment of CKD.The NLRP3 inflammasome activation amplifies the inflammation response, promoting pyroptotic cell death. Thus, it may contribute to the onset and progression of CKD, but the mechanism behind inflammasome activation in CKD remains obscure.In this review, we summarized recent findings on the role of the NLRP3 inflammasome in CKD and new strategies targeting the NLRP3 inflammasome.
Insights
Chronic kidney disease (CKD) involves inflammation, often driven by the NLRP3 inflammasome. Targeting this inflammasome offers promising new treatments for kidney disease.
Area of Science:
- Nephrology
- Immunology
- Molecular Biology
Background:
- Chronic kidney disease (CKD) is a global health issue characterized by inflammation and toxin accumulation.
- Inflammation in CKD contributes to kidney dysfunction and fibrosis.
- The NLR family pyrin domain containing 3 (NLRP3) inflammasome is implicated in renal inflammation.
Purpose of the Study:
- To review current knowledge on the role of the NLRP3 inflammasome in CKD.
- To explore novel therapeutic strategies targeting the NLRP3 inflammasome for CKD treatment.
Main Methods:
- Literature review of recent findings on NLRP3 inflammasome activation in CKD.
- Analysis of studies investigating small molecule inhibitors of the NLRP3 inflammasome.
Main Results:
- NLRP3 inflammasome activation exacerbates renal inflammation and promotes pyroptotic cell death in CKD.
- The precise mechanisms of inflammasome activation in CKD require further elucidation.
- Small molecule inhibitors targeting NLRP3 show potential for CKD treatment.
Conclusions:
- The NLRP3 inflammasome is a key mediator in the pathogenesis of CKD.
- Targeting the NLRP3 inflammasome represents a promising therapeutic avenue for managing CKD.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome I : Introduction
Nephrons

